Additional file 4 of CDK5 promotes apoptosis and attenuates chemoresistance in gastric cancer via E2F1 signaling

NIAID Data Ecosystem2026-05-01 收录

数据链接：

https://figshare.com/articles/dataset/Additional_file_4_of_CDK5_promotes_apoptosis_and_attenuates_chemoresistance_in_gastric_cancer_via_E2F1_signaling/26643250 数据链接链接失效反馈

官方服务：

资源简介：

Additional file 4: Table S4: Reagents and Kits.

创建时间：

2023-11-21

Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in non-small cell lung cancer

化疗耐药机制

多组学整合分析

Continuous exposure to cisplatin can induce drug resistance to limit efficacy, however, the underlying mechanisms correlated to cisplatin resistance are still unclear. Drug-sensitive A549 cells and ci

NIAID Data Ecosystem70

A novel mTORC1-GRASP55 signaling axis reshapes the extracellular proteome upon stress. Nüchel et al.

非经典蛋白分泌调控

细胞信号通路

Cells communicate with their environment via surface proteins and secreted factors. However, how environmental cues modify the extracellular proteome is not known. Unconventional protein secretion (UP

NIAID Data Ecosystem30

DataSheet9_Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.ZIP

化疗耐药机制

AKT信号通路

SHP2 mediates signaling from multiple receptor tyrosine kinases (RTKs) to extracellular signal-regulated kinase (ERK) and Ser and Thr kinase AKT, and its inhibitors offer an unprecedented opportunity

NIAID Data Ecosystem10

Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy

化疗耐药机制

IFN-γ信号通路

"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,

NIAID Data Ecosystem40

Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]

化疗耐药机制

表观遗传调控

Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have uncovered the alternations of HER2 and assoc

NIAID Data Ecosystem20

Additional file 4 of CDK5 promotes apoptosis and attenuates chemoresistance in gastric cancer via E2F1 signaling

资源简介：

相关数据集